Navigation Links
Jennerex Appoints James M. Burke, M.D. Vice President, Clinical Research
Date:2/22/2011

SAN FRANCISCO, Feb. 22, 2011 /PRNewswire/ -- Jennerex, Inc. (San Francisco), a clinical-stage cancer biotherapeutics company, today announced the appointment of James M. Burke, M.D. to the newly-created position of vice president, clinical research. Dr. Burke will be responsible for all global clinical research activities related to Jennerex pipeline compounds.

"Dr. Burke has been working with Jennerex in an advisory capacity as a clinical advisor for over a year, and has provided significant contributions to the strategic direction and clinical development of JX-594 for the treatment of liver cancer, and we look forward to bringing his expertise in-house," said David H. Kirn, M.D., president and chief executive officer of Jennerex. "In addition, as we advance our earlier stage pipeline products, Dr. Burke's direct clinical research experience using immunotherapeutics to treat multiple solid tumors will be instrumental as we pursue continued development of JX-929, JX-1395 and our next generation products."

Dr. Burke brings approximately 20 years of experience in basic and applied clinical science of genetic and immunotherapy.  His clinical research using immunotherapeutics including oncolytic viruses for the treatment of various cancers have advanced the understanding of the medical applications for oncolytic virus therapy. Prior to Jennerex, Dr. Burke was the Director of Cancer Research at Billings Clinic, where he was also a clinical investigator for JX-594. He had previously served as associate director of clinical research at Cell Genesys, Inc., where he was responsible for the development of the oncolytic adenovirus platform of agents and other gene therapy vaccines for the treatment of cancer and other diseases.  In addition, after completing his Hematology and Oncology Fellowship at UC San Francisco (UCSF), he was an attending physician at UCSF in the department of hematology and oncology. He received his M.D. from Georgeto
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Jennerex and Transgene Enter Into an Exclusive Partnership for the Development and Commercialization of JX-594 for the Treatment of Cancers
2. Jennerex Completes Fully Subscribed Private Placement for Aggregate Gross Proceeds of $8.6 Million
3. Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
4. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
5. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
6. Jennerex Closes $5 Million First Tranche of Series C Financing
7. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
8. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
9. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
10. ALS Therapy Development Institute Appoints Anil Godhwani to Board of Directors
11. Amarin Corporation Appoints Industry Veteran Paul E. Huff as Chief Commercial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... , May 05, 2015 Research and Markets ... addition of the "Clinical Laboratory, Molecular Diagnostics ... 2015 to 2019 - Europe Version" report ... especially in the area of molecular diagnostics and ... and evolving world market that is moving out ...
(Date:5/5/2015)... May 05, 2015 Exotic ... distributor, announces the launch of http://www.cng.exoticautomation.com , ... with a convenient way to purchase genuine OEM ... . , The new website provides owners ... with direct access to high performance products for ...
(Date:5/5/2015)... MA (PRWEB) May 05, 2015 The ... ), a Massachusetts-based non-profit operating in the public interest, ... affiliate of the Hearst Communications Company, have formed a ... for public outreach and education across the healthcare and ... for the voice of patients and the public to ...
(Date:5/4/2015)...   St. Jude Children,s Research Hospital ... for finding genetic alterations that play an important ... identify with whole-genome sequencing. The findings appear today ... The tool is an algorithm called ... Tree in Next Generation Sequencing. ...
Breaking Biology Technology:European Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market 2015-2019 2Exotic Automation & Supply Launches Ecommerce Website 2ACRES and San Antonio Express-News Launch Blog on Accountability in Clinical Research 2ACRES and San Antonio Express-News Launch Blog on Accountability in Clinical Research 3ACRES and San Antonio Express-News Launch Blog on Accountability in Clinical Research 4Scientists dramatically improve method for finding common genetic alterations in tumors 2Scientists dramatically improve method for finding common genetic alterations in tumors 3Scientists dramatically improve method for finding common genetic alterations in tumors 4
... Nov. 27 Corium International, Inc.,a privately-held transdermal ... Gardner, M.D. and Daniel G. Welch to the ... Essex Woodlands Health,Ventures, is a Professor of Medicine ... of cell biology and pharmacology. In addition to,her ...
... Therapeutics,(Nasdaq: FOLD ) today announced that it will host ... 7:00 PM at the Four Seasons Hotel in New,York City. ... the,Phase 2 clinical trials performed for Amigal(TM) (migalastat hydrochloride),for Fabry ... other,research and development programs at the company., A live ...
... an FDA 510(k) (Pre-Market Notification), Pathway for AppyScore(TM), the First Blood-based ... ... ROCK, Colo., Nov. 27 AspenBio Pharma,Inc. (Nasdaq: APPY ) ... diagnostics for animals and humans, has,received an official response from the ...
Cached Biology Technology:Corium International, Inc. Announces Appointment of Phyllis Gardner, M.D. and Daniel G. Welch to Board 2Corium International, Inc. Announces Appointment of Phyllis Gardner, M.D. and Daniel G. Welch to Board 3Amicus Therapeutics to Host R&D Day 2Amicus Therapeutics to Host R&D Day 3AspenBio Pharma Pursues FDA 510(k) Application Pathway for Appendicitis Blood Test 2AspenBio Pharma Pursues FDA 510(k) Application Pathway for Appendicitis Blood Test 3AspenBio Pharma Pursues FDA 510(k) Application Pathway for Appendicitis Blood Test 4
(Date:4/9/2015)... , April 9, 2015 Synaptics Inc. (NASDAQ: ... solutions, announced today that it will report financial results ... April 23, 2015, after the close of market. The ... and investors at 2:00 p.m. PT (5:00 p.m. ET), ... To participate on the live call, analysts and ...
(Date:4/2/2015)... , April 2, 2015 According ... 2015 attributed to somewhat higher than 125 MSEK. This ... year-end report 2014 that revenues for Q1 2015 would ... company reported for Q4 2014. The operating result for ... negative. The complete interim report will as previously communicated ...
(Date:3/31/2015)... 31, 2015   Guidepoint , a leading global ... Post-Surgical Pain Management TRACKER, part of the Guidepoint ... in the medical device and therapeutics markets. The Post-Surgical ... treatment volumes, market share, and adoption rates across three ... joint surgery. The Post-Surgical Pain Management TRACKER ...
Breaking Biology News(10 mins):Synaptics to Report Third Quarter Results on April 23 2Fingerprint Cards Revises Revenues for Q1 2015 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3
... Washington, DC Engineered nanoscale materials (ENMs), which ... use in food packaging, raise new safety evaluation ... report released today by the Project on Emerging ... The food-packaging industry, food companies and ...
... developed an effective technology for reducing contamination of dangerous ... Salmonella and E. coli O157:H7 on foods ranging from ... It is made from inexpensive and readily available ingredients ... and Drug Administration. The new technology, which ...
... Almost every June for 30 years, Terry McEneaney drove around ... three routes. Park ornithologist at the time, he would ... Then he,d drive another half mile, repeat the process and ... for the North American Breeding Bird Survey. Trying to finish ...
Cached Biology News:Use of nanomaterials in food packaging poses regulatory challenges 2New UGA invention effectively kills foodborne pathogens in minutes 2Bird watchers, space technology come together in Montana State University study 2Bird watchers, space technology come together in Montana State University study 3
... AGI provides both long and short-term ... laboratory animals in both quarantine and non-quarantine ... services are also available utilizing our state-of-the-art ... AGI is equipped with on site CDC ...
... SYBR Green I nucleic acid gel stain ... stain that has bright fluorescence when bound to ... ideal for detecting dsDNA in gels using laser ... nucleic acid stain has also found uses in ...
... Environment 2) Dot plot, Contour plot, ... Compensation 4) Cell Cycle 5) ... Intelligent batch generation of graphs and statistics ... drag-and-drop operations to perform complex batch analyses ...
... cross-linking techniques are defined by the author ... Wong. This valuable hardcover guide includes hundreds ... application references. More than 300 pages detail ... conjugate preparation from selection and design ...
Biology Products: